CLAIMS

1. Use of the composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.

2. The use of claim 1, wherein the vector is a viral vector or a non-viral vector.

3. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.

4. The use of claim 3, wherein the vector is a viral vector or a non-viral vector.

5. Use of the composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.

6. The use of claim 5, wherein the glia are astrocytes or microglia.

7. Use of the composition comprising neurons or glia having Nurr1 gene introduced thereinto in the manufacture of a medicament for inhibiting tau protein accumulation, aggregation, or tangle.

8. The use of claim 7, wherein the glia are astrocytes or microglia.

9. Use of the composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for inhibiting tau protein phosphorylation.

10. The use of claim 9, wherein the vector is a viral vector or a non-viral vector.

11. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for inhibiting tau protein phosphorylation.

12. The use of claim 11, wherein the vector is a viral vector or a non-viral vector.

13. Use of the composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in

the manufacture of a medicament for inhibiting tau protein phosphorylation.

14. The use of claim 13, wherein the glia are astrocytes or microglia.

15. Use of the composition comprising neurons or glia having a Nurr1 gene introduced thereinto in the manufacture of a medicament for inhibiting tau protein phosphorylation.

16. The use of claim 15, wherein the glia are astrocytes or microglia.

17. Use of the composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein accumulation, aggregation, or tangle.

18. The use of claim 17, wherein the vector is a viral vector or a non-viral vector.

19. Use of the composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein

accumulation, aggregation, or tangle.

20. The use of claim 19, wherein the vector is a viral vector or a non-viral vector.

21. Use of the composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein accumulation, aggregation, or tangle.

22. The use of claim 21, wherein the glia are astrocytes or microglia.

23. Use of the composition comprising neurons or glia having a Nurr1 gene introduced thereinto in the manufacture of a medicament for prevention or treatment of a disease caused by tau protein accumulation, aggregation, or tangle.

24. The use of claim 23, wherein the glia are astrocytes or microglia.

25. Use of the pharmaceutical composition comprising a vector carrying Nurr1 and Foxa2 genes in the manufacture

of a medicament for prevention or treatment of tauopathy.

26. Use of the pharmaceutical composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of tauopathy.

27. Use of the pharmaceutical composition comprising neurons or glia having Nurr1 and Foxa2 genes introduced thereinto in the manufacture of a medicament for prevention or treatment of tauopathy.

28. Use of the pharmaceutical composition comprising a vector carrying a Nurr1 gene in the manufacture of a medicament for prevention or treatment of tauopathy.

29. The use of any one of claims 25 to 28, wherein the tauopathy is a disease selected from the group consisting of tau-positive Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia (FTD), multi-Infarct dementia (MID), frontotemporal lobar degeneration (FTLD), progressive cupranuclear palsy (PSP), Pick’s disease, chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), globular glial tauopathy, Huntington's disease, ganglioglioma, gangliocytoma, primary age-related tauopathy (PART), argyrophilic grain disease,

lead encephalopathy, lipofuscinosis, Lytico-Bodig disease, and meningioangiomatosis.